Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer

NCT04918186 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

60

Enrollment

NETWORK

Sponsor class

Conditions

Ovarian Cancer

Interventions

DRUG: Durvalumab
DRUG: BA3011
DRUG: BA3021
DRUG: ENB003
DRUG: Toripalimab

Sponsor

Canadian Cancer Trials Group

Collaborators

[object Object]
[object Object]
[object Object]